The association of smoking status with hospitalisation for COVID-19 compared with other

respiratory viruses a year previous: A case-control study at a single UK National Health

Service trust

David Simons*[1,2], Olga Perski*[3], Lion Shahab[3], Jamie Brown[3] and Robin Bailey[2,4]

[1] Centre for Emerging, Endemic and Exotic Diseases, RVC, UK

[2] Hospital for Tropical Diseases, London, UK

[3] Department of Behavioural Science and Health, University College London, UK

[4] London School of Hygiene and Tropical Medicine, UK

*These authors contributed equally to this work

Abstract word count: 250

Manuscript word count: 3317

Key words: tobacco, smoking, COVID-19, case-control study, hospitalisation

Abstract

Background: It is unclear whether smoking increases the risk of COVID-19 hospitalisation. We

aimed to i) examine the association of smoking status with hospitalisation for COVID-19 compared

with hospitalisation for other respiratory virus infections a year previous; ii) compare current

smoking in cases with age- and sex-matched London prevalence; and iii) examine concordance

between smoking status recorded on the electronic health record (EHR) and the medical notes.

Methods: This retrospective case-control study enrolled adult patients (446 cases and 211

controls) at a single National Health Service trust in London, UK. London smoking prevalence was

obtained from the representative Annual Population Survey. The outcome variable was type of

hospitalisation (COVID-19 vs. another respiratory virus). The exposure variable was smoking

status (never/former/current smoker). Logistic regression analyses adjusted for age, sex,

socioeconomic position and comorbidities were performed. The study protocol and analyses were pre-registered on the Open Science Framework.

Findings: Patients hospitalised with COVID-19 had lower odds of being current smokers than patients admitted with other respiratory viruses (OR_{adj}=0.55, 95% CI=0.31-0.96, p=.04). Odds were equivocal for former smokers (OR_{adj}=1.08, 95% CI=0.72-1.65, p=.70). Current smoking in cases was significantly lower than expected from London prevalence (9.4% vs. 12.9%, p=.02). Smoking status recorded on the EHR deviated significantly from that recorded within the medical notes ($\chi^2(3)$=226.7, p<.001).

Interpretation: In a single hospital trust in the UK, patients hospitalised with COVID-19 had reduced odds of being current smokers compared with patients admitted with other respiratory viruses a year previous.

Funding: UK BBSRC, Cancer Research UK, UKPRP.

INTRODUCTION

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. There are in excess of 50 million confirmed COVID-19 cases globally, with over one million deaths reported[1]. Large age and sex differences in case severity and mortality have been observed[2], with hypertension, diabetes and obesity identified as important risk factors[3]. There are *a priori* reasons to believe that current smokers are at increased risk of contracting COVID-19 and experiencing greater disease severity once infected. SARS-CoV-2 enters epithelial cells through the ACE-2 receptor[4]. Evidence suggests that gene expression and subsequent ACE-2 receptor levels are elevated in the airway and oral epithelium of current smokers[5, 6], potentially making smokers vulnerable to contracting SARS-CoV-2. The regular hand-to-mouth movements involved in cigarette smoking may also increase SARS-CoV-2 transmission. Other studies, however, show that smoking downregulates the ACE-2 receptor[7]. These uncertainties notwithstanding, both former and

current smoking increase the risk of other respiratory viral[8] and bacterial[9] infections and are

associated with worse outcomes once infected. For example, a large observational study in the UK

found that former and current smokers had increased odds of being hospitalised with community-

acquired pneumonia compared with never smokers[10]. However, early data from the ongoing

pandemic have not provided clear evidence for an independent association of smoking status with

COVID-19 outcomes[11, 12].

A living evidence review of observational and experimental studies examining the association of

smoking status with COVID-19 infection, hospitalisation, disease severity and mortality has found

that, among 279 studies, current smoking (not adjusted for age, sex or comorbidities) was

generally lower than what would be expected from national smoking prevalence[12]. In addition,

current smokers were at reduced risk of testing positive for SARS-CoV-2 compared with never

smokers, and former smokers were at increased risk of hospitalisation, disease severity and in-

hospital mortality compared with never smokers. However, the majority of included studies were

limited by the lack of appropriate controls, poor recording of smoking status and insufficient

adjustment for relevant covariates. Many studies relied on routine electronic health records (EHRs)

to obtain individual-level data on demographic characteristics, comorbidities and smoking status.

Previous research suggests that data on smoking status obtained via EHRs tend to be incomplete

or outright inaccurate, with implausible longitudinal changes observed[13]. In addition, as

hospitalised populations differ by age and sex from the general population, comparisons of current

and former smoking prevalence in hospitalised and non-hospitalised populations are likely limited.

There is hence an urgent need for alternative study designs with relevant comparator groups (e.g.

populations hospitalised with a similar type of respiratory viral infection) and adjustment for

covariates to better understand the association of smoking status with COVID-19 disease

outcomes.

We therefore aimed to i) examine, in a retrospective case-control study conducted at a single UK

hospital trust, the association of smoking status with hospitalisation for COVID-19 compared with

hospitalisation for other respiratory virus infections (e.g. influenza, respiratory syncytial virus) a

year previous; ii) compare current smoking prevalence in the case population with age- and sex-

matched London prevalence, with estimates obtained from the nationally representative Annual

Population Survey; and iii) examine whether there is discordance between smoking status

recorded on the summary EHR and within the contemporaneous medical notes.

METHODS

Study design

This was an observational, retrospective, case-control study performed at a single National Health

Service (NHS) hospital trust (comprising two hospital sites) in London, UK. The study protocol and

analysis plan were pre-registered on the Open Science Framework (https://bit.ly/3kFYh06). The

pre-registered protocol stipulated a non-inferiority design (i.e. a one-tailed statistical test) to

maximise statistical power to detect a significantly lower proportion of current smokers among

patients hospitalised with COVID-19 compared with patients hospitalised with another respiratory

viral infection a year previous. The protocol was amended after data collection but prior to

statistical analysis (https://osf.io/ezfqs/) to implement a traditional case-control design (i.e. a two-

tailed statistical test), as a delay in study approval meant that the number of eligible cases and

controls exceeded our expectations. Hence, the obtained sample size was deemed sufficient for a

two-tailed test. A completed STROBE checklist is available in the additional file. This amended

study was designed to test the hypothesis that current smoking is underrepresented in patients

hospitalised with COVID-19 compared with those hospitalised with other respiratory viruses a year

previous. Ethical approval was obtained from a local research committee and the NHS Health

Research Authority (IRAS_282704). The requirement for informed consent was waived due to the

nature of the study.

For comparison, aggregated data on current, former and never smoking prevalence for London

was obtained from the Office for National Statistics (ONS) Annual Population Survey[14].

A sample size calculation, updated after data collection but prior to data analysis

(https://osf.io/ezfqs/), indicated that 363 cases and 109 controls would provide 80% power to

detect a 10% reduction in current smoking prevalence in cases compared with controls (i.e. 10% in

cases and 20% in controls) with alpha set to 5%. We included all cases from 1st March 2020 to the

26th August 2020 (the date on which data were obtained) and all controls from the 1st January 2019

and the 31st December 2019.

Eligibility criteria

Inclusion criteria

• Cases

1. Consecutive patients admitted to an adult hospital ward (i.e. 18+ years) between 1st

124   March 2020 and 26th August 2020 (the date on which data were obtained);

125   2. Diagnosis of COVID-19 on or within 5 days of hospital admission, identified via

126   associated International Classification of Diseases version 10 (ICD-10) codes[15].

127   This temporal boundary was set to prevent inclusion of patents with nosocomial

128   (hospital-acquired) infection and allowed for a delay of 3 days in requesting a

129   COVID-19 test and 2 days for receiving and reporting the results on the EHR. The

130   median incubation time for COVID-19 is estimated at 5.1 days (95% CI = 4.5-

131   5.8)[16]. We sought to exclude individuals with nosocomial COVID-19 infection as

132   they are a different population (e.g. older, more frail) compared with those infected

133   in the community and subsequently requiring hospitalisation.

135   • Controls

136   1. Consecutive patients admitted to an adult hospital ward (i.e. 18+ years) between 1st

137   January 2019 and 31st December 2019;

138   2. Diagnosis of a viral respiratory infection (e.g. influenza, parainfluenza) on or within 5

139   days of admission, identified via ICD-10 codes. Patients hospitalised with

respiratory viruses other than COVID-19 were deemed appropriate controls due to

the similar mechanism for transmission (i.e. respiratory droplets and aerosols)[17].

In addition, risk factors for hospitalisation with other respiratory viruses are similar to

those for hospitalisation with COVID-19 (e.g. age, comorbidities)[18, 19].

Exclusion criteria

• Cases and controls

1. No record of smoking status on the summary EHR or within the medical notes;

2. A primary diagnosis of infectious exacerbation of COPD due to the strong causal

association of COPD with current and former smoking.

Measures

Data on demographic and smoking characteristics were collected from the summary EHR or the

medical notes. In the UK, the summary EHR is produced at the point of an individual's first

interaction with a specific NHS hospital trust. Further information is added to the summary EHR

following subsequent interactions with the hospital trust. The medical notes include

contemporaneous clinical notes, General Practitioner referral letters and outpatient clinic letters,

and are updated more frequently than the summary EHR.

Outcome variable

The outcome of interest was the type of hospital admission (i.e. with COVID-19 vs. other

respiratory viral infections).

Exposure variable

Smoking status (i.e. current, former, never) was obtained from the summary EHR or the medical

notes. A number of cases were recorded as 'non-smokers' without distinguishing between 'former

smokers' and 'never smokers'. For the primary analysis, patients categorised as a 'non-smoker'

were treated as 'never smokers'. Where possible, information on use of smokeless tobacco,

waterpipe and/or alternative nicotine products (e.g. e-cigarettes) was extracted. The joint first

authors searched within the contemporaneous medical records for free-text entries of smoking

status. The most recently available record of smoking status, obtained from either the summary

EHR or the medical notes, was extracted. Where available, data on pack-year history of smoking

were extracted.

Covariates

Covariates included age, sex, ethnicity, socioeconomic position (with post codes linked by the

research team to the Index of Multiple Deprivation (IMD)[20]) and comorbidities (classified by

organ system, including cardiac, metabolic and respiratory diseases). Medical conditions not

expected to be strongly associated with COVID-19 hospitalisation were not considered in the

analyses (e.g. sciatica and fibromyalgia; see the additional file). Age was treated as a continuous

variable in the primary analysis, with banded age groups (i.e. 18-29 years, 30-44 years, 45-59

years, 60-74 years, 75-89 years and > 90 years) used in exploratory analyses. The IMD was

categorised as quintiles to reduce the impact of sparse data.

Data analysis

All analyses were conducted in R version 4.0.2.[21] Descriptive statistics for cases and controls are

reported. To explore differences between cases and controls, Pearson's Chi-square tests,

Cochran-Armitage tests for trend and ANOVAs were used, as appropriate.

To examine the association of former and current smoking with hospitalisation for COVID-19

compared with hospitalisation for other respiratory virus infections, unadjusted and adjusted

generalised linear models with a binomial distribution and logit link function were performed. We

report odds ratios (ORs), 95% confidence intervals (CIs) and *p*-values. Two sensitivity analyses

were performed. First, those recorded as 'non-smokers' were removed from the analysis. Second,

those excluded from the analytic sample due to missing data on smoking status (see section above

on 'Exclusion criteria') were included and coded as i) 'never smokers' and then as ii) 'current

smokers'.

We then compared age-stratified current smoking prevalence in the case population with overall

London prevalence stratified by age and weighted by the sex distribution of the case population.

To examine the concordance between smoking status recorded on the summary EHR and within

the contemporaneous medical notes, Pearson's Chi-squared tests were performed for the entire

sample, and then separately for cases and controls.

RESULTS

A total of 610 potential cases and 514 potential controls were identified. A total of 446 cases and

211 controls were included in the analytic sample (see Figure 1). Thirteen potential controls and 60

potential cases were excluded due to not having a record of documented smoking status. This was

likely due to these patients having no prior contact with the selected NHS foundation trust. Notably,

37 (62%) of potential cases that were excluded because of missing smoking status did not survive

to hospital discharge, with no in-hospital mortality in potential controls, which suggests that data

were not missing at random.

Figure 1. Eligibility flow diagram for controls (left hand side) and cases (right hand side).

Compared with controls, cases were more likely to be male (55% vs. 35.9%) and older (64.9 years

vs 62.5 years) (see Table 1). Approximately 10% of cases and controls had missing data for

ethnicity. Compared with cases, controls were more likely to be admitted from more deprived areas

(IMD quintiles 1 and 2) (41.8% vs. 32.9%, $p < 0.001$) and have pre-existing metabolic (30.3% vs

13.3%) and cardiac comorbidities (53.4% vs 30.3%). A significantly larger proportion of cases

compared with controls did not survive to discharge (28.7% vs. 4.3%). Among 128 cases not

surviving to discharge, 53 (41.4%) were never smokers, 63 (49.2%) were former smokers and 12

(9.4%) were current smokers. For patients who survived to discharge, the median length of

hospital stay for cases and controls was 9 (IQR = 4-18) and 4 (IQR = 2-9) days, respectively (see

Table 1).

 Table 1. Demographic and smoking characteristics of cases and controls.

	Controls (N=211)	Cases (N=446)	Total (N=657)	*p* value
Female sex	116 (55.0%)	160 (35.9%)	276 (42.0%)	< 0.001
Age in years (continuous)				0.019
- Median (IQR)	62.5 (48.5-75.8)	64.9 (52.4-76.2)	64.58 (51.3-76.1)	
Age in years (banded)				0.007
- 18-29	18 (8.5%)	11 (2.5%)	29 (4.4%)	
- 30-44	22 (10.4%)	37 (8.3%)	59 (9.0%)	
- 45-59	46 (21.8%)	113 (25.3%)	159 (24.2%)	
- 60-74	67 (31.8%)	162 (36.3%)	229 (34.9%)	
- 75+	58 (27.5%)	123 (27.6%)	181 (27.5%)	
Ethnicity				0.243
- Black British, Black African or Black Caribbean	19 (9.0%)	63 (14.1%)	82 (12.5%)	
- White British or White Other	116 (55.0%)	220 (49.3%)	336 (51.1%)	
- Not stated	26 (12.3%)	43 (9.6%)	69 (10.5%)	
- Asian British or Asian	28 (13.3%)	68 (15.2%)	96 (14.6%)	
- Other	22 (10.4%)	52 (11.7%)	74 (11.3%)	
IMD quintile				0.06
- Missing*	5 (2.4%)	5 (1.1%)	10 (1.5%)	
- 1 - Most deprived	21 (10.0%)	26 (5.8%)	47 (7.2%)	
- 2	67 (31.8%)	121 (27.1%)	188 (28.6%)	
- 3	42 (19.9%)	122 (27.4%)	164 (25.0%)	
- 4	38 (18.0%)	98 (22.0%)	136 (20.7%)	
- 5 - Least deprived	38 (18.0%)	74 (16.6%)	112 (17.0%)	
Most recent record of smoking status (summary EHR or medical notes)				0.012
- Never smoker	108 (51.2%)	232 (52.0%)	340 (51.8%)	
- Former smoker	67 (31.8%)	172 (38.6%)	239 (36.4%)	
- Current smoker	36 (17.1%)	42 (9.4%)	78 (11.9%)	
Record of pack-year smoking history in former and current smokers	36 (35%)	91 (42.5%)	127 (40%)	
- Pack-year smoking history in current smokers, median (IQR)	30 (22.5-45)	30 (6-45)	30 (16.8-45.5)	
- Pack-year smoking history in former smokers, median (IQR)	20 (10-40)	25 (10-40)	25 (10-40)	
Recorded smoking status on summary EHR				< 0.001
- Never smoker	23 (10.9%)	233 (52.2%)	256 (39.0%)	
- Former smoker	22 (10.4%)	152 (34.1%)	174 (26.5%)	
- Current smoker	7 (3.3%)	30 (6.7%)	37 (5.6%)	
- Unknown	159 (75.4%)	31 (7.0%)	190 (28.9%)	
Survival to discharge	202 (95.7%)	318 (71.3%)	520 (79.1%)	< 0.001
Length of hospital admission for survivors (days)				< 0.001
- Median (IQR)	4 (2-9)	9 (4-18)	7 (3-14)	
Cancer (current or past)	66 (31.3%)	90 (20.2%)	156 (23.7%)	0.002
Auto-immune disease (present)	12 (5.7%)	16 (3.6%)	28 (4.3%)	0.213
Metabolic disease (present)	28 (13.3%)	135 (30.3%)	163 (24.8%)	< 0.001
Haematological disease (present)	3 (1.4%)	4 (0.9%)	7 (1.1%)	0.541
Cardiac disease (present)	64 (30.3%)	238 (53.4%)	302 (46.0%)	< 0.001
Neurological disease (present)	24 (11.4%)	54 (12.1%)	78 (11.9%)	0.786
Respiratory disease (present)	54 (25.6%)	91 (20.4%)	145 (22.1%)	0.134

Renal disease (present)	12 (5.7%)	37 (8.3%)	49 (7.5%)	0.235
HIV (present)	2 (0.9%)	7 (1.6%)	9 (1.4%)	0.522
No relevant comorbidities	43 (20.4%)	85 (19.1%)	128 (19.5%)	0.690

* IMD is not available for individuals with home addresses outside of England.

Cases and controls were predominantly admitted from North central and North East central London

(see additional file figure 1). The number of cases admitted from peripheral locations was greater

than in controls and represents transfer of inpatients from other hospitals and diversion of patients

that would otherwise have attended local hospitals due to bed pressures. The Chi-square test for

trend found inconclusive evidence for any difference in socioeconomic position between cases and

controls, $\chi^2(3) = 8.93$, $p = 0.06$ (see additional file figure 2).

Association of smoking status with type of hospitalisation

The prevalence of former smoking was higher in cases compared with controls (38.6% vs. 31.8%).

Current smoking prevalence was lower in cases compared with controls (9.4% vs. 17.1%). A single

patient from the case cohort was recorded as a dual cigarette and e-cigarette user. Two patients,

one from each cohort, were recorded as dual cigarette and shisha/waterpipe users. Pack-year

history of smoking was only recorded for 40% of patients with a smoking history (see Table 1).

In the univariable analysis, patients hospitalised with COVID-19 had reduced odds of being a

current smoker compared with those admitted with other respiratory viruses (OR = 0.52, 95% CI =

0.31-0.86, $p = 0.01$). The odds for former smokers were equivocal (OR = 1.16, 95% CI = 0.81-

1.68, $p = 0.43$).

In the multivariable analysis adjusted for sex, age, socioeconomic position and comorbidities,

patients hospitalised with COVID-19 had reduced odds of being a current smoker compared with

those admitted with other respiratory viruses (OR = 0.55, 95% CI = 0.31-0.96, $p = 0.04$). The odds

for former smokers were equivocal (OR = 1.08, 95% C.I. = 0.72-1.61, $p = 0.70$).

Sensitivity analyses

First, in a sensitivity analysis with patients recorded as 'non-smokers' excluded from the sample

(leaving 398 cases and 159 controls), patients hospitalised with COVID-19 had reduced odds of

being a current smoker compared with those admitted with other respiratory viruses (OR = 0.41,

95% CI = 0.22-0.74, $p = 0.03$). The odds for former smokers were equivocal (OR = 0.78, 95% C.I.

= 0.49-1.23, $p = 0.28$).

Second, in a sensitivity analysis with those with missing data on smoking status (n = 73) treated as

'never smokers' (resulting in 506 cases and 224 controls), patients hospitalised with COVID-19 had

reduced odds of being a current smoker compared with those admitted with other respiratory

viruses (OR = 0.51, 95% CI = 0.30-0.88, $p = 0.01$). Next, when those with missing data on smoking

status were treated as 'current smokers', patients hospitalised with COVID-19 had equivocal odds

of being a current smoker compared with those admitted with other respiratory viruses (OR = 0.94,

95% CI = 0.61-1.46, $p = 0.80$).

Comparison with London smoking prevalence

Compared with age-stratified London prevalence weighted by sex, similar current smoking

prevalence in cases were observed in the 30-44 years, 60-74 years and 75+ years age groups

(see Table 2). Current smokers were overrepresented in the 18-29 years age group and

underrepresented in the 45-59 years age group. Former smokers were consistently

overrepresented in cases compared with age-stratified London prevalence weighted by sex, except

for those aged 18-29 years.

277
278

279 *Table 2.* Smoking prevalence in cases and controls compared with London prevalence.

	Controls			Cases			London*		
Age	Current smoker	Former smoker	Never smoker	Current smoker	Former smoker	Never smoker	Current smoker	Former smoker	Never smoker
18-29	3 (15%)	2 (10%)	15 (75%)	6 (50%)	0 (0%)	6 (50%)	17%	7.3%	75.7%
30-44	7 (30.4%)	1 (4.3%)	15 (65.2%)	6 (13.3%)	11 (24.4%)	28 (62.2%)	14.7%	17.2%	68%
45-59	9 (18%)	14 (28%)	27 (54%)	5 (4.5%)	35 (31.2%)	72 (64.3%)	14.5%	23.3%	62.2%
60-74	13 (21%)	22 (35.5%)	27 (43.5%)	15 (9.5%)	60 (38%)	83 (52.5%)	11.6%	32.5%	56%
75+	4 (7.1%)	28 (50%)	24 (42.9%)	10 (8.4%)	66 (55.5%)	43 (36.1%)	6.8%	37.3%	56%

* Age-stratified London prevalence weighted by the sex distribution of the case population (see
additional file table 1 for weightings).

Concordance of smoking status recorded on the summary EHR and the medical notes

Controls were more likely to have no record of smoking status on the summary EHR compared

with cases (75.4% vs. 7%) (see Figure 2). Smoking status on the summary EHR was incorrectly

recorded for 168 controls and 60 cases (χ^2(3) = 226.7, *p* = < 0.001). In cases, six current smokers

were misclassified as former smokers, one current smoker as a never smoker and six current

smokers had no record of smoking status on the summary EHR. In controls, six current smokers

were misclassified as former smokers and 23 current smokers had no record of smoking status on

the summary EHR. There was greater discordance between smoking status recorded on the

summary EHR and within the medical notes in controls (χ^2(3) = 256.5, *p* = < 0.001) than in cases

(χ^2(3) = 34.2, *p* = < 0.001).

Figure 2. Concordance between smoking status recorded on the summary EHR and the medical notes for controls (red) and cases (blue).

DISCUSSION

This observational, retrospective, case-control study with patients admitted to a single UK hospital trust found a lower proportion of current smokers in cases hospitalised with COVID-19 during the first phase of the pandemic compared with controls hospitalised with other respiratory viral infections a year previous. The observed reduction in current smoking prevalence was robust to adjustment for sex, age, socioeconomic position and comorbidities. The low prevalence of current smoking in cases appeared driven by current smokers being underrepresented in those aged 45-59 years, with similar to expected current smoking prevalence in the other age groups. It should be noted that cases aged 45-59 years were more likely to reside in less deprived areas than controls. As smoking status is strongly associated with socioeconomic position[14], this may partly explain the lower smoking prevalence in this age group.

Further, we found that smoking status is typically poorly recorded in the summary EHR. This was more prominent in controls than cases – a difference that is likely explained by the observation that

COVID-19 patients were followed up by the respiratory medicine team after discharge as part of a

COVID-19 follow-up clinic where they specifically asked about smoking status[22]. The observed

discrepancy between smoking status recorded on summary EHRs and the contemporaneous

medical notes is a concern, particularly for studies relying solely on EHRs as the source of

information on smoking status.

Strengths and limitations

To our knowledge, this is one of few studies specifically designed to examine the association

between smoking status and hospitalisation with COVID-19. It was further strengthened by the

inclusion of a control population hospitalised with other respiratory viruses, a comparison with local

smoking prevalence derived from a nationally representative survey and an assessment of the

quality of data on smoking status gleaned from summary EHRs.

This study also had a number of limitations. First, current smoking is expected *a priori* to be

associated with hospitalisation for non-COVID-19 respiratory viruses[23]. Hence, the use of this

control population may have biased towards the null any association between smoking status and

type of hospitalisation due to greater smoking prevalence in controls compared with the general

population at risk of COVID-19[24]. To minimise any impact of this on the interpretation of results,

we included a community-level comparator of overall London smoking prevalence. Second, the

IMD was used to capture the socioeconomic position of patients, calculated for a spatial boundary

referred to as a Lower Layer Super Output Area[20], which are geographic areas of populations of

~1500 individuals, which can then be linked to post codes. In densely populated and

socioeconomically diverse areas such as central London, the ability of the IMD to capture

socioeconomic position may be limited[25]. Third, the control population was selected to reflect

commonalities in the transmission of respiratory viruses. However, emerging evidence suggests

that COVID-19 has a significantly different pathological process compared with other respiratory

viruses. For example, mortality rates from COVID-19 differ widely from those due to epidemic

influenza[26]. Further, mortality rates for COVID-19 differ between and within countries and over

the course of the pandemic, at least partly due to improving knowledge and treatment of the

disease[27]. In addition, the risk of superadded bacterial infection in COVID-19 patients appears

lower than for those with influenza[28]] and COVID-19 patients have increased rates of

coagulopathies compared with other respiratory viruses[29]. Taken together, these emerging

observations may limit any direct comparison of risk profiles in cases and controls. Fourth, a

history of current or past cancer was high in both groups at greater than 20% and was significantly

greater in controls compared with cases. This reflects a bias in the population that regularly

interacts with the selected NHS hospital trust, which is a specialist cancer referral centre. We

visualised the geographic regions where patients were admitted from to examine any systemic

differences between cases and controls, and caution that the differing catchment areas of the two

cohorts may have led to important differences in the underlying populations. In addition, during the

peak of the first wave of the pandemic in the UK, many cases were transferred across hospital

sites due to bed pressures.

Implications for policy and practice

COVID-19 will continue to place a large burden on healthcare services in the UK and

internationally over the coming months and years. To mitigate against this, multiple non-

pharmacological interventions are being implemented to reduce the intensity of demand on acute

and intensive services. Irrespective of any direct link between smoking and COVID-19 disease

outcomes, smoking is a significant cause for healthcare demand globally. We have argued

elsewhere for the need to ramp up smoking cessation support to reduce the current and future

burden on healthcare and social services[30].

Avenues for future research

To better understand the role of smoking as a risk factor for COVID-19 hospitalisation, longitudinal,

representative population-level studies from multiple sites are required. A large, multinational

clinical cohort study (the International Severe Acute Respiratory and emerging Infection

Consortium; ISARIC) collects smoking status but this is likely obtained from summary EHRs.

Purposeful acquisition of accurate smoking status is required to characterise the role of smoking in

COVID-19 disease outcomes.

Conclusion

In a single hospital trust in the UK, patients hospitalised with COVID-19 had reduced odds of being

current smokers compared with patients admitted with other respiratory viruses a year previous. In

the 45-59 year age group, lower smoking prevalence than would be expected based on age- and

sex-matched local smoking prevalence was observed. Smoking status was poorly recorded, with

high observed discordance between smoking status recorded on the summary EHR and the

medical notes.

DATA SHARING

Anonymised and de-identified individual-level data are available upon request and approval from

the NHS foundation trust. Requests should be directed to the corresponding author. Alternatively,

data can be requested directly from the Biomedical Research Centre Clinical and Research

Informatics Unit at UCL/UCLH.

CONTRIBUTERS

DS, OP, LS, JB and RB conceived of and designed the study. DS and RB acquired the study data.

DS and OP extracted and analysed the data. DS, OP, LS, JB contributed to the interpretation of

the data and to the drafting of the manuscript. All authors have read and approved the manuscript.

DECLARATION OF INTERESTS

DS, OP and RB have no conflicts of interest to declare. LS has received a research grant and

honoraria for a talk and travel expenses from manufacturers of smoking cessation medications

(Pfizer and Johnson & Johnson). JB has received unrestricted research funding to study smoking

cessation from companies who manufacture smoking cessation medications. All authors declare

no financial links with tobacco companies or e-cigarette manufacturers or their representatives.

ACKNOWLEDGEMENTS

DS is supported by a PhD studentship from the UK Biotechnology and Biological Sciences

Research Council [BB/M009513/1]. OP receives salary support from Cancer Research UK

(C1417/A22962). JB, LS, & OP are members of SPECTRUM, a UK Prevention Research

Partnership Consortium (MR/S037519/1). UKPRP is an initiative funded by the UK Research and

Innovation Councils, the Department of Health and Social Care (England) and the UK devolved

administrations, and leading health research charities.

ROLE OF FUNDERS

We gratefully acknowledge all funding listed above. The views expressed are those of the authors

and not necessarily those of the funders.

ETHICAL APPROVAL

Ethical approval was obtained from a local research committee and the NHS Health Research

Authority (IRAS_282704). The requirement for informed consent was waived due to the nature of

the study.

REFERENCES
1. COVID-19 Map. Johns Hopkins Coronavirus Resource Center.
https://coronavirus.jhu.edu/map.html. Accessed 1 Oct 2020.

2. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590
patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55.
doi:10.1183/13993003.00547-2020.

3. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at
increased risk for COVID-19 infection? Lancet Respir Med. 2020;:0.

4. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2
Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease
Inhibitor. Cell. 2020;181:271-280.e8.

5. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking Upregulates
Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus
SARS-CoV-2 (Covid-19. J Clin Med. 2020;9, Page 841:841.

6. Cai G. Bulk and Single-Cell Transcriptomics Identify Tobacco-Use Disparity in Lung Gene
Expression of ACE2, the Receptor of 2019-nCov. preprint. LIFE SCIENCES; 2020.
doi:10.20944/preprints202002.0051.v3;
http://web.archive.org/web/20200925104805/https://www.preprints.org/manuscript/202002.0051/v3
.

7. Oakes JM, Fuchs RM, Gardner JD, Lazartigues E, Yue X. Nicotine and the renin-angiotensin
system. Am J Physiol - Regul Integr Comp Physiol. 2018;315:895–906.

8. Abadom TR, Smith AD, Tempia S, Madhi SA, Cohen C, Cohen AL. Risk factors associated with
hospitalisation for influenza-associated severe acute respiratory illness in South Africa: A case-
population study. Vaccine. 2016;34:5649–55.

9. Feldman C, Anderson R. Cigarette smoking and mechanisms of susceptibility to infections of the
respiratory tract and other organ systems. J Infect. 2013;67:169–84.

10. Millett ERC, De Stavola BL, Quint JK, Smeeth L, Thomas SL. Risk factors for hospital
admission in the 28 days following a community-acquired pneumonia diagnosis in older adults, and
their contribution to increasing hospitalisation rates over time: A cohort study. BMJ Open.
2015;5:008737.

11. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob
Induc Dis. 2020;18:20.

12. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2
infection, hospitalisation and mortality from COVID-19: A living rapid evidence review with
Bayesian meta-analyses (version 9). Qeios. 2020. doi:10.32388/UJR2AW.10.

13. Polubriaginof F, Salmasian H, Albert DA, Vawdrey DK. Challenges with Collecting Smoking
Status in Electronic Health Records. AMIA Annu Symp Proc. 2018;2017:1392–400.

14. ONS. Adult smoking habits in the UK: 2019. Office for National Statistics; 2020.
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpecta
ncies/bulletins/adultsmokinghabitsingreatbritain/2019. Accessed 10 Jul 2020.

15. ICD-10 Version:2019. https://icd.who.int/browse10/2019/en#/U07.1. Accessed 28 Oct 2020.

16. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of
Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and
Application. Ann Intern Med. 2020;172:577–82.

17. McCarthy N, Giesecke J. Case-case comparisons to study causation of common infectious
diseases. Int J Epidemiol. 1999;28:764–8.

18. Peralta PS-O, Cortes-García M, Vicente-Herrero M, Castrillo-Villamandos C, Arias-Bohigas P,
Amo IP, et al. Risk factors for disease severity among hospitalised patients with 2009 pandemic
influenza A (H1N1) in Spain, April – December 2009. Eurosurveillance. 2010;15:19667.

19. Falsey AR, McElhaney JE, Beran J, van Essen GA, Duval X, Esen M, et al. Respiratory
Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe
Influenza-like Illness. J Infect Dis. 2014;209:1873–81.

20. The English Indices of Deprivation 2019. :31.

21. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R
Foundation for Statistical Computing; 2020. https://www.R-project.org/.

22. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. 'Long-COVID': a cross-
sectional study of persisting symptoms, biomarker and imaging abnormalities following
hospitalisation for COVID-19. Thorax. 2020. doi:10.1136/thoraxjnl-2020-215818.

23. Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote
infection, lung disease and cancer. Nat Rev Immunol. 2009;9:377–84.

24. Vandenbroucke JP, Pearce N. Case–control studies: basic concepts. Int J Epidemiol.
2012;41:1480–9.

25. Deas I, Robson B, Wong C, Bradford M. Measuring Neighbourhood Deprivation: A Critique of
the Index of Multiple Deprivation. Environ Plan C Gov Policy. 2003;21:883–903.

26. ONS. Deaths due to coronavirus (COVID-19) compared with deaths from influenza and
pneumonia, England and Wales.
https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins
/deathsduetocoronaviruscovid19comparedwithdeathsfrominfluenzaandpneumoniaenglandandwale
s/deathsoccurringbetween1januaryand31august2020. Accessed 29 Oct 2020.

27. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G.
ASSESSING THE AGE SPECIFICITY OF INFECTION FATALITY RATES FOR COVID-19:
SYSTEMATIC REVIEW, META-ANALYSIS, AND PUBLIC POLICY IMPLICATIONS. medRxiv.
2020;:2020.07.23.20160895.

28. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic
review and meta-analysis. J Infect. 2020;81:266–75.

29. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al.
Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res.
2020;191:145–7.

30. Simons D, Perski O, Brown J. Covid-19: The role of smoking cessation during respiratory virus
epidemics. The BMJ. 2020. https://blogs.bmj.com/bmj/2020/03/20/covid-19-the-role-of-smoking-
cessation-during-respiratory-virus-epidemics/.

Figure 1. Primary location of residence of controls (L) and cases (R) enrolled in the study. The location of the study site is marked by a black dot. n.b. visualised region is limited to central London.

Figure 2. IMD quintile for admitted controls and cases for each age group.

504 **Table 1.** Weightings matching London APS data to case population

APS age band	Sex	n	Proportion
18-29	Male	10	0.83
	Female	2	0.17
30-44	Male	28	0.62
	Female	17	0.38
45-59	Male	79	0.71
	Female	33	0.29
60-74	Male	101	0.64
	Female	57	0.36
75+	Male	68	0.57
	Female	51	0.43

ICD-10 code list:

- Cases
- U07.1 - COVID-19, virus identified
- Controls
- J10.1 - Influenza with other respiratory manifestations, seasonal influenza virus identified
- J10.0 - Influenza with pneumonia, seasonal influenza virus identified
- J11.0 - Influenza with pneumonia, virus not identified
- J12.2 - Parainfluenza virus pneumonia
- J12.0 - Adenoviral pneumonia
- J10.8 - Influenza with other manifestations, seasonal influenza virus identified
- J11.1 - Influenza with other respiratory manifestations, virus not identified
- J12.8 - Other viral pneumonia
- J12.9 - Viral pneumonia, unspecified
- J12.3 - Human metapneumovirus
- J20.8 - Acute bronchitis due to other specified organisms
- J21.8 - Acute bronchiolitis due to other specified organisms

Comorbidity code list:

- Auto-immune
- Myasthenia gravis
- Systemic Lupus Erythematosus
- Crohn's
- disease
- Ulcerative colitis
- Granulomatosis with Polyangiitis
- Sjogren's syndrome
- Cold agglutinin disease
- Grave's disease
- Rheumatoid arthritis
- Cancers
- All cancers
- All carcinomas
- All myelodysplasias
- Waldenstrom's macroglobulinaemia
- All myelomas
- All lymphomas
- All leukaemias
- Gliomas
- Sarcomas
- Melanomas
- Cardiac

o Hypertension
o Ischaemic heart disease
o Coronary artery disease
o Atrial fibrillation
o Congestive cardiac failure
o All other heart failure
o Non-ST elevation myocardial infarction
o Myocarditis
o History of coronary artery bypass graft
o Aortic stenosis
o Other valvular abnormalities
o Presence of a pacemaker/implantable cardiac defibrillator
o All cardiomyopathies
o Structural cardiac abnormalities

• Haematological
o Sickle cell disease
o All thalassaemias
o Thrombotic thombocytopenia purpura
o Anaemia

• Metabolic
o Obesity
o Type-1 Diabetes Mellitus
o Type-2 Diabetes Mellitues
o Syndrome of inappropriate ADH
o Hypothyroidism
o Addison's disease
o Pituitary hormone abnormalities
o Chronic pancreatitis

• Neurological
o History of acute stroke
o Parkinson's disease
o History of transient ischaemic attack
o Multiple sclerosis
o Epilepsy
o Cerebral Palsy
o All dementias
o Autism
o Ataxic disorders

• No relevant comorbidities
o Nil
o Alcohol excess
o Achalasia
o Sciatica
o Substance misuse
o Benign prostatic hypertrophy

• Psychiatric
o Schizophrenic disorders
o Anorexia nervosa

• Renal
o Chronic kidney disease
o History of acute kidney disease
o Renal transplant

• Respiratory
o Obstructive sleep apnoea
o Pulmonary hypertension
o Chronic obstructive pulmonary disease
o Asthma
o Pulmonary fibrosis
o Bronchiectasis
o Interstitial lung disease
o Emphysema
o History of or current tuberculosis
o Sarcoidosis

609   o   History of pulmonary embolus